MiR-542-3p overexpression is associated with enhanced osteosarcoma cell proliferation and migration ability by targeting Van Goghlike 2

Molecular Medicine Reports

Volumn 11, Issue 2, 2015, Pages 851-856

  Li, Huazhuang ^a   Liu, Hongtao ^b   Pei, Jingfang ^b   Wang, Haiyan ^b   Lv, Honglin ^b  

^a YIDU CENTRAL HOSPITAL OF WEIFANG   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

3' untranslated region; MicroRNA; Migration; Osteosarcoma; Proliferation; Van Goghlike 2

Indexed keywords

MEMBRANE PROTEIN; MICRORNA; SIGNAL PEPTIDE; VANGL2 PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL MOTION; CELL PROLIFERATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PATHOLOGY; SEQUENCE ALIGNMENT; TUMOR CELL LINE;

BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICRORNAS; OSTEOSARCOMA; SEQUENCE ALIGNMENT; TRANSFECTION;

EID: 84916200157     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2777     Document Type: Article

References (18)

1. Hauben EI, Weeden S, Pringle J, Van Marck EA and Hogendoorn PC: Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 38: 1218-1225, 2002.
2. Hamada K, Tomita Y, et al: Evaluation of chemotherapy response in osteosarcoma with FDG-PET. Ann Nucl Med 23: 89-95, 2009.
3. Tabone MD, Kalifa C, Rodary C, et al: Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 12: 2614-2620, 1994.
4. Longhi A, Errani C, et al: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32: 423-436, 2006.
5. Lal A, et al: miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to 'seedless' 3'UTR microRNA recognition elements. Mol Cell 35: 610-625, 2009.
6. Zhao Y, Samal E and Srivastava D: Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436: 214-220, 2005.
7. Calin GA and Croce CM: MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66: 7390-7394, 2006.
8. Ikeda S, Kong SW, Lu J, et al: Altered microRNA expression in human heart disease. Physiol Genomics 31: 367-373, 2007.
9. Maire G, Martin JW, et al: Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet 204: 138-146, 2011.
10. Jones KB, et al: miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res 72: 1865-1877, 2012.
11. Namløs HM, Meza-Zepeda LA, Barøy T, et al: Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One 7: e48086, 2012.
12. Doench JG and Sharp PA: Specificity of microRNA target selection in translational repression. Genes Dev 18: 504-511, 2004.
13. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.
14. Wang R, Wang HB, et al: MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PLoS One 7: e46173, 2012.
15. Hu Y, Liu CM, et al: Two common SNPs in pri-miR-125a alter the mature miRNA expression and associate with recurrent pregnancy loss in a Han-Chinese population. RNA Biol 8: 861-872, 2011.
16. Paul S and Dey A: Wnt signaling and cancer development: therapeutic implication. Neoplasma 55: 165-176, 2008.
17. McQueen P, Ghaffar S, et al: The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther 11: 1223-1232, 2011.
18. Nishita M, Enomoto M, Yamagata K and Minami Y: Cell/tissue-tropic functions of Wnt5a signaling in normal and cancer cells. Trends Cell Biol 20: 346-354, 2010.